Literature DB >> 21088815

[Jehova's Witnesses and severe injury with impending hemorrhaging : how complex is the treatment?].

C Zeckey1, N Vanin, G Neitzke, P Mommsen, S Bachmann, M Frink, M Wilhelmi, C Krettek, F Hildebrand.   

Abstract

Hemorrhage is frequently seen during the early phases of polytrauma management and intensive care treatment of the severely injured. Traumatic coagulopathy as well as the sometimes overlooked hyperfibrinolysis may lead to further complications. Therefore, transfusion of blood products and coagulation factors is often crucial. Jehova's Witnesses reject transfusions of blood and blood products due to religious convictions. In this case report a therapeutic approach of a multiple trauma patient suffering from traumatic brain injury, blunt chest trauma and liver laceration is described, who has been treated without blood products. As one main focus, ethical as well as legal aspects are discussed. Beside therapeutic concepts, such as the administration of coagulation factors, recombinant erythropoietin and iron, ethical and legal aspects remain part of the controversial discussion.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21088815     DOI: 10.1007/s00104-010-1999-y

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  7 in total

1.  Use of recombinant human erythropoietin (r-HuEPO) in a Jehovah's Witness refusing transfusion of blood products: case report.

Authors:  J A Koestner; L D Nelson; J A Morris; K Safcsak
Journal:  J Trauma       Date:  1990-11

Review 2.  Erythropoietin: structure, control of production, and function.

Authors:  W Jelkmann
Journal:  Physiol Rev       Date:  1992-04       Impact factor: 37.312

3.  Consensus statement: using epoetin alfa to decrease the risk of allogeneic blood transfusion in the surgical setting. Roundtable of Experts in Surgery Blood Management.

Authors:  K Messmer
Journal:  Semin Hematol       Date:  1996-04       Impact factor: 3.851

4.  [Management of polytrauma].

Authors:  D Nast-Kolb; S Ruchholtz; C Waydhas; G Taeger
Journal:  Chirurg       Date:  2006-09       Impact factor: 0.955

5.  Severe anemia in the Jehovah's Witness: case report and discussion.

Authors:  S L Collins; G A Timberlake
Journal:  Am J Crit Care       Date:  1993-05       Impact factor: 2.228

6.  The effect of patient size and dose of recombinant human erythropoietin therapy on red blood cell volume expansion in autologous blood donors for elective orthopedic operation.

Authors:  L T Goodnough; D Verbrugge; R E Marcus; V Goldberg
Journal:  J Am Coll Surg       Date:  1994-08       Impact factor: 6.113

Review 7.  The role of erythropoietin in the acute phase of trauma management: evidence today.

Authors:  N K Kanakaris; G Petsatodis; B Chalidis; N Manidakis; G Kontakis; P V Giannoudis
Journal:  Injury       Date:  2008-12-30       Impact factor: 2.586

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.